Memory follicular helper T (memory Tfh) cells exist as a retained local pool in the lymphoid organ that drained the original antigen and as a circulating pool in blood and spleen; the two subsets have different effector biases (plasma-cell promotion versus secondary germinal-center support) and are intertwined with similarly subdivided memory B cells. This problem asks for the mechanisms that create and maintain this 'memory anatomy': which priming cues assign a Tfh precursor to the retained-local versus releasable-circulating fate, which cells carry the persistent cognate peptide–MHC class II (pMHCII) depots that retain local memory Tfh cells, how long these depots persist and what controls their decay, how universal surrogate markers for the two memory B-cell subsets can be defined, how generalizable the subdivision is across antigens, routes and adjuvants, and how vaccine formulations could rationally bias recall toward rapid high-affinity antibody production versus germinal-center rediversification. The question originates from Asrir et al. (Nature Communications, 2017) and, despite substantial confirmatory and adjacent progress in mice and humans, its causal mechanistic core remains unresolved.

Background

T follicular helper (Tfh) cells are CD4+ T cells that express the chemokine receptor CXCR5 and the inhibitory receptor PD-1, migrate into B-cell follicles of lymphoid organs, and provide help (CD40 ligand, IL-21, other signals) to B cells; this help drives the germinal center (GC) reaction, the specialized microanatomy in which B cells undergo somatic hypermutation and affinity-based selection to produce high-affinity antibodies and long-lived memory. After an immune response resolves, memory Tfh cells persist in two interconnected compartments: a local pool retained in the draining lymph node (dLN), the organ that collected antigen from the immunization or infection site, and a circulating pool found in blood and spleen. Asrir, Aloulou, Gador, Pérals and Fazilleau (Nature Communications 8:847, 2017) showed in mice that local memory Tfh cells promote more plasma-cell (antibody-secreting cell) differentiation on rechallenge, whereas circulating memory Tfh cells secrete more IFN-γ and IL-21 and better support secondary GCs. In parallel, local memory B cells were homogeneous and class-switched, programmed for rapid plasma-cell differentiation, while circulating memory B cells were heterogeneous, largely IgM-bearing, and about one third able to re-enter GCs and rediversify their receptors. Mechanistically, local memory Tfh cells carried higher-affinity T-cell receptors (TCRs, the antigen receptor of T cells), cognate peptide–MHC class II complexes (pMHCII: antigenic peptide fragments displayed on MHC class II molecules, recognized by CD4+ TCRs) were detected at the surface of antigen-specific memory B cells in the dLN but not elsewhere, and blocking TCR–pMHCII interactions in vivo released local memory Tfh cells into the circulation. This suggested that persistent pMHCII 'depots' on memory B cells act as a retention mechanism that filters the local memory Tfh pool by TCR affinity, analogous to how tissue-resident memory CD8+ T cells are held in peripheral tissues. The authors proposed that this anatomy matters for vaccination: creating local antigen depots or adding adjuvant components such as CpG (a synthetic oligodeoxynucleotide that activates the innate receptor TLR9 and skews immunity) might control the size and quality of the protective circulating memory pool. Several mechanistic questions were explicitly raised but not resolved: how the anatomy is programmed during priming (timing of co-stimulation, asymmetric cell divisions), the precise cellular source, longevity and decay control of the pMHCII depots over months, how general the subdivision is across antigens, routes and adjuvants, and how recall quality could be rationally biased by vaccine design; in addition, the reported markers and isotype associations of the two memory B-cell subsets were debated, leaving open whether reliable universal surrogate markers distinguish them. Later work has confirmed and extended the phenomenon without answering the causal questions: long-lived local Tfh cells persist for over a year in mice once protected from a cell-death artifact during tissue isolation (Künzli et al., Science Immunology 2020), a memory-Tfh transcriptional program emerges on GC collapse with skewed high-affinity TCR assortment in the local compartment (Robinson et al., Science Immunology 2022), lymph-node Tfh cells persist for at least six months after mRNA vaccination in humans (Mudd et al., Cell 2022), B-cell-dependent tissue-resident helper cells exist in lung iBALT (inducible bronchus-associated lymphoid tissue; Swarnalekha et al., Science Immunology 2021), and subcapsular sinus macrophages (CD169+ phagocytes lining the lymph-node sinus) direct location-dependent memory B-cell recall in mice and humans (Moran et al., Nature Communications 2018; Dhenni et al., Cell 2025). None of these identifies the priming program that assigns retained versus releasable fate or quantifies depot decay.

Problem Statement

The problem, as raised by Asrir et al. (2017) and still open, is to give a causal mechanistic account of the local-versus-circulating subdivision of memory Tfh cells — a common objective with the following linked, source-faithful sub-questions: (1) Programming: which molecular cues, timing of co-stimulation, and asymmetric cell divisions (mitoses that partition fate determinants unequally between daughter cells) during priming and the effector phase causally determine whether a given Tfh precursor becomes a retained local memory cell (held in the draining lymphoid organ) versus a releasable circulating memory cell? (2) Depot maintenance: which antigen-presenting cell (APC) types display long-term cognate peptide–MHC class II in the memory phase, how long and at what quantity do these pMHCII depots persist in draining sites over months, and what controls their decay (the source paper detected them only on antigen-specific memory B cells and showed that blocking TCR–pMHCII interaction releases local memory Tfh cells, but did not measure depot dynamics)? (3) Markers and coupling: do reliable, universal surrogate markers distinguish the two functionally distinct memory B-cell subsets (local plasma-cell-prone versus circulating rediversification-prone) across antigens and adjuvants — and if so, which markers and with what required discrimination — given that existing markers and isotype associations are debated, and how do those memory B-cell properties mechanistically instruct memory Tfh retention or release? (4) Generalizability: how general is the local/circulating memory Tfh balance and its functional bias across diverse antigens, routes of infection or immunization, and adjuvants? (5) Exploitation: how can vaccine formulations be rationally designed — for example by manipulating depot formation, pMHCII display, or adjuvant components such as CpG — to bias recall toward rapid protective high-affinity antibody production versus secondary germinal-center-mediated rediversification? A complete account must address all five of these linked sub-questions together; the minimum for each is: sub-question 1 is complete when it identifies the priming cues that assign the retained-local versus releasable-circulating fate and the stage at which they act; sub-question 2 is complete when it identifies which antigen-presenting cell types carry the memory-phase pMHCII depots and states how long those depots persist and what controls their decay; sub-question 3 is complete when it settles whether reliable, universal surrogate markers distinguish the two subsets and, if so, which markers and with what required discrimination, and states how those memory B-cell properties instruct retention or release; sub-question 4 is complete when it states the antigens, routes and adjuvants its generality claim covers — at minimum more than one antigen and more than one route or adjuvant — or shows that the subdivision does not generalize; sub-question 5 is complete when it states the design changes it proposes and the recall outcome each is meant to produce. Covering only some of the sub-questions, or treating any single one as sufficient on its own, does not resolve the problem.

References

  1. Asrir A, Aloulou M, Gador M, Pérals C, Fazilleau N. Interconnected subsets of memory follicular helper T cells have different effector functions. Nature Communications 8:847 (2017). DOI: 10.1038/s41467-017-00843-7. https://doi.org/10.1038/s41467-017-00843-7
  2. Künzli M, Schreiner D, Pereboom TC, Swarnalekha N, Litzler LC, Lötscher J, Ertuna YI, Roux J, Geier F, Jakob RP, Maier T, Hess C, Taylor JJ, King CG. Long-lived T follicular helper cells retain plasticity and help sustain humoral immunity. Science Immunology 5:eaay5552 (2020). DOI: 10.1126/sciimmunol.aay5552. https://doi.org/10.1126/sciimmunol.aay5552
  3. Robinson AM, Higgins BW, Shuparski AG, Miller KB, McHeyzer-Williams LJ, McHeyzer-Williams MG. Evolution of antigen-specific follicular helper T cell transcription from effector function to memory. Science Immunology 7:eabm2084 (2022). DOI: 10.1126/sciimmunol.abm2084. https://doi.org/10.1126/sciimmunol.abm2084
  4. Mudd PA, Minervina AA, Pogorelyy MV, Turner JS, Kim W, Kalaidina E, Petersen J, Schmitz AJ, Lei T, Haile A, Kirk AM, Mettelman RC, Crawford JC, Nguyen THO, Rowntree LC, Rosati E, Richards KA, Sant AJ, Klebert MK, Suessen T, Middleton WD, Estepp JH, Schultz-Cherry S, McGargill MA, Gaur A, Hoffman J, Mori M, Tang L, Tuomanen E, Webby R, Hayden RT, Hakim H, Hijano DR, Allison KJ, Allen EK, Bajracharya R, Awad W, Van de Velde L, Clark BL, Wilson TL, Souquette A, Castellaw A, Dallas RH, Gowen A, Fabrizio TP, Lin CY, Brice DC, Cherry S, Roubidoux EK, Cortez V, Freiden P, Wohlgemuth N, Whitt K, Wolf J, Teefey SA, O'Halloran JA, Presti RM, Kedzierska K, Rossjohn J, Thomas PG, Ellebedy AH. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell 185:603–613.e15 (2022). DOI: 10.1016/j.cell.2021.12.026. https://doi.org/10.1016/j.cell.2021.12.026
  5. Swarnalekha N, Schreiner D, Litzler LC, Iftikhar S, Kirchmeier D, Künzli M, Son YM, Sun J, Moreira EA, King CG. T resident helper cells promote humoral responses in the lung. Science Immunology 6:eabb6808 (2021). DOI: 10.1126/sciimmunol.abb6808. https://doi.org/10.1126/sciimmunol.abb6808
  6. Beura LK, Fares-Frederickson NJ, Steinert EM, Scott MC, Thompson EA, Fraser KA, Schenkel JM, Vezys V, Masopust D. CD4+ resident memory T cells dominate immunosurveillance and orchestrate local recall responses. Journal of Experimental Medicine 216:1214–1229 (2019). DOI: 10.1084/jem.20181365. https://doi.org/10.1084/jem.20181365
  7. Moran I, Nguyen A, Khoo WH, Butt D, Bourne K, Young C, Hermes JR, Biro M, Gracie G, Ma CS, Munier CML, Luciani F, Zaunders J, Parker A, Kelleher AD, Tangye SG, Croucher PI, Brink R, Read MN, Phan TG. Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes. Nature Communications 9:3372 (2018). DOI: 10.1038/s41467-018-05772-7. https://doi.org/10.1038/s41467-018-05772-7
  8. Dhenni R, Carey Hoppé A, Reynaldi A, Kyaw W, Handoko NT, Grootveld AK, Keith YH, Bhattacharyya ND, Ahel HI, Telfser AJ, McCorkindale AN, Yazar S, Bui CHT, Smith JT, Khoo WH, Boyd M, Obeid S, Milner B, Starr M, Brilot F, Milogiannakis V, Akerman A, Aggarwal A, Davenport MP, Deenick EK, Chaffer CL, Croucher PI, Brink R, Goldstein LD, Cromer D, Turville SG, Kelleher AD, Venturi V, Munier CML, Phan TG. Macrophages direct location-dependent recall of B cell memory to vaccination. Cell 188:3477–3496.e22 (2025). DOI: 10.1016/j.cell.2025.04.005. https://doi.org/10.1016/j.cell.2025.04.005
  9. Dhenni R, Phan TG. The geography of memory B cell reactivation in vaccine-induced immunity and in autoimmune disease relapses. Immunological Reviews 296:62–86 (2020). DOI: 10.1111/imr.12862. https://doi.org/10.1111/imr.12862
  10. Chong AS, Ansari MJ. Heterogeneity of memory B cells. American Journal of Transplantation 18:779–784 (2018). DOI: 10.1111/ajt.14669. https://doi.org/10.1111/ajt.14669
  11. Priest D, Wing J. Heterogeneity of memory B cells in human blood. International Immunology 38:348–356 (2026). DOI: 10.1093/intimm/dxag006. https://doi.org/10.1093/intimm/dxag006
  12. Schroeder AR, Zhu F, Hu H. Stepwise Tfh cell differentiation revisited: new advances and long-standing questions. Faculty Reviews 10:3 (2021). DOI: 10.12703/r/10-3. https://doi.org/10.12703/r/10-3
  13. Linterman MA, Yu D, Webb LMC, Vinuesa CG. Targeting T follicular helper cells for lifelong health. Nature Reviews Drug Discovery (2026). DOI: 10.1038/s41573-026-01495-3. https://doi.org/10.1038/s41573-026-01495-3